ReviewFrontiers in public health2022
HPV Vaccination in Kenya: The Challenges Faced and Strategies to Increase Uptake.
Review in Frontiers in public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 3 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Human papillomavirus vaccination uptake and determinant factors among adolescent schoolgirls in sub-Saharan Africa: A systematic review and meta-analysis.Human vaccines & immunotherapeutics · 2024Pooled it
- Uptake of human papilloma virus vaccine and its determinants among females in East Africa: a systematic review and meta-analysis.BMC public health · 2024Pooled it
- The impact of the COVID-19 pandemic on cancer care including innovations implemented in Sub-Saharan Africa: A systematic review.Journal of global health · 2023Pooled it
- Knowledge, perceptions, uptake, and determinants of HPV vaccination, and preferred delivery strategies among out-of-school girls in Masaka, Uganda.Human vaccines & immunotherapeutics · 2026Article
- Bridging the service gap: health facility challenges in HPV vaccine uptake in rural Uganda.BMC women's health · 2026Article
- Determinants of human papillomavirus vaccine non-uptake among adolescent girls in Ethiopia: evidence from National Immunization Survey.BMJ open · 2026Article
- Impact of the COVID-19 Pandemic on HPV Vaccination in Low- and Middle-Income Countries: A Scoping Review.Vaccines · 2026Review
- Community engagement for vaccine delivery in low- and middle-income countries and humanitarian settings: A scoping umbrella review.PLOS global public health · 2026Article
- Bacterial vaginosis and specific high-risk human papillomavirus genotype infection: a cross-sectional study in Nairobi, Kenya.Frontiers in global women's health · 2026Article
- Molecular Insights into HPV-Driven Head and Neck Cancers: From Viral Oncoproteins to Precision Therapeutics.Viruses · 2025Review
- HPV infection patterns and viral load distribution: implication on cervical cancer prevention in Western Kenya.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2025Article
- HPV genotypes in Africa: comprehensive analysis of genetic diversity and evolutionary dynamics.Archives of virology · 2025Article
- Papillomavirus Vaccination Programs and Knowledge Gaps as Barriers to Implementation: A Systematic Review.Vaccines · 2025Review
- Overcoming HPV vaccine hesitancy: insights from a successful school-based vaccination campaign in the Saa health district of Cameroon.BMC infectious diseases · 2025Article
- Understanding Kenyan policymakers' perspectives about the introduction of new maternal vaccines.Health policy and planning · 2025Article
- Strengthening vaccine uptake: a qualitative assessment of community health worker educational resource needs and community perspectives on vaccination in Western Kenya.Frontiers in public health · 2025Article
- Text messaging to improve uptake of human papillomavirus vaccination: a study among adolescent girls living with HIV in Kisumu county.Ecancermedicalscience · 2025Article
- Acceptability of single-dose HPV vaccination schedule among health-care professionals in Kenya: a mixed-methods study.Journal of the National Cancer Institute. Monographs · 2024Article
- Article
- Prevalence and genotype distribution of potential high-risk and high-risk human papillomavirus among women attending selected reproductive health clinics in lake victoria basin-kenya: a cross-sectional study.BMC women's health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human papilloma virus (HPV) is the leading cause of ano-genital cancers globally with cervical cancer as the top cause of cancer- related deaths in women. Over 90% of these deaths occur in low income countries where cancer control strategies remain inadequate. HPV vaccination provides protection against HPV types 16 and 18 which are responsible for approximately 70% of cervical cancer cases. The optimal age of vaccination is in the early adolescent period, before sexual debut with possible HPV infection. Studies have shown that children residing in low income settlements are at risk of early initiation of sexual activity. Adolescent vaccination programs would provide an avenue to link other health promotion strategies targeting this age group that has hitherto been left out of many health interventions in 2019, Kenya introduced HPV vaccine to be given to 10 year old girls. Uptake has been sub-optimal with only 33% of targeted population receiving the first dose in 2020 and 16% returning for the 2nd dose. While disruption of immunization programs by the COVID-19 pandemic contributed to the low coverage, other factors such as low demand fuelled by misinformation have also played a role.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.